Sun Pharmaceuticals Q1 Results FY26: Q1 PAT Rose -19.64% to ₹2,278.63 Crore; Revenue Surged 9.47% YoY

Sun Pharmaceuticals Q1 Results FY26: Sun Pharmaceuticals posted its Q1 results on 31st July 2025. The company posted robust numbers, with Q1 PAT standing at ₹2,278.63 crores against revenue of ₹13,851.4 crores. During Q1 FY26, the profit increase of the company was recorded at -19.64% YoY, and the revenue increase for the same period was 9.47%. 

Sun Pharmaceuticals Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

(Figures in crores)

Sun Pharmaceuticals Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

(Figures in crores)

Sun Pharmaceuticals Results FY26 Highlights (Q1 FY26 vs FY25)

• Sun Pharmaceuticals clocked Q1 FY26 consolidated revenue of ₹13,851.4 crores vs ₹12,652.75 crores. 
• On the profit front, Sun Pharmaceuticals earned a consolidated PAT of ₹2,278.63 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹2,835.62 crore. 
• Consolidated PAT rose for the first quarter of FY26, was -19.64% YoY, and revenue soared 9.47% YoY. 
• As per the standalone figures, the quarterly PAT of Sun Pharmaceuticals has increased by 216.85%, and revenue has surged by 24.54% YoY.

Sun Pharmaceuticals Share Price Performance

On the opening bell of 31st July 2025, the shares of Sun Pharmaceuticals opened at ₹1,715 per share. However, the initial gains are sustained as of now, and Sun Pharmaceuticals shares are trading at ₹1,706.70 per share, lower than their opening price. 

Considering the long-term performance, Sun Pharmaceuticals shares have yielded returns of approximately 0.12% over the past year, and 5-year returns stand at 230.58%. Over the maximum timeframe, Sun Pharmaceuticals shares provided investors with 12,622.80% returns. However, one must ignore the risk of volatility in the stock market and invest in Sun Pharmaceuticals shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your research before investing in shares and other securities.

Also Read : SAIL Q1 Results FY26: Q1 PAT Rose 810.47% to ₹744.58 Crore; Revenue Surged 8.02% YoY

Recent Articles

Flysbs Aviation IPO GMP & Review: Apply or Avoid?

New India Assurance Company Q1 Results FY26: Q1 PAT Surged 67.29% to ₹400.33 Crore; Revenue Soared 10.26% YoY

Sri Lotus Developers IPO GMP: Day 1 IPO Live Updates

Varun Beverages Q1 Results FY26: Q1 PAT Surged 5.14% to ₹1,317.02 Crore; Revenue Dropped 2.33% YoY

Takyon Networks IPO GMP: Day 1 IPO Live Updates

Asian Paints Q1 Results FY26: Q1 PAT Plunged 6.00% to ₹1,099.77 Crore; Revenue Dropped 0.35% YoY